Cyclacel Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Cyclacel Pharmaceuticals, Inc.‘s stocks are currently a part of 10 hedge funds’ portfolios, which represents 5.55% of the total amount of its stocks outstanding. This makes up a total of 624.62K shares of Cyclacel Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -74.57% or -1.83M shares fewer. As for the holding position changes, 40% (4) of current hedge fund investors increased the number of shares held, 10% (1) of current holders sold a part of the shares held, and 40% (4) closed the holdings completely.
Hedge funds holding Cyclacel Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 13 |
|---|---|
| Q3 2018 | 11 |
| Q4 2018 | 11 |
| Q1 2019 | 12 |
| Q2 2019 | 9 |
| Q3 2019 | 9 |
| Q4 2019 | 9 |
| Q1 2020 | 7 |
| Q2 2020 | 7 |
| Q3 2020 | 5 |
| Q4 2020 | 13 |
| Q1 2021 | 30 |
| Q2 2021 | 26 |
| Q3 2021 | 27 |
| Q4 2021 | 28 |
| Q1 2022 | 25 |
| Q2 2022 | 21 |
| Q3 2022 | 25 |
| Q4 2022 | 27 |
| Q1 2023 | 10 |
Hedge funds changes in Cyclacel Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 3 | 3 | 2 | 2 | 3 |
|---|---|---|---|---|---|
| Q3 2018 | 1 | 4 | 2 | 3 | 1 |
| Q4 2018 | 4 | 3 | 1 | 4 | -1 |
| Q1 2019 | 4 | 3 | 3 | 3 | -1 |
| Q2 2019 | 2 | 4 | 1 | 5 | -3 |
| Q3 2019 | 3 | 1 | 1 | 3 | 1 |
| Q4 2019 | 2 | 2 | 2 | 2 | 1 |
| Q1 2020 | 1 | 2 | 0 | 2 | 2 |
| Q2 2020 | 7 | 0 | 0 | 8 | -8 |
| Q3 2020 | 2 | 1 | 1 | 4 | -3 |
| Q4 2020 | 11 | 1 | 0 | 3 | -2 |
| Q1 2021 | 20 | 6 | 4 | 3 | -3 |
| Q2 2021 | 6 | 7 | 10 | 10 | -7 |
| Q3 2021 | 5 | 8 | 8 | 4 | 2 |
| Q4 2021 | 5 | 7 | 6 | 4 | 6 |
| Q1 2022 | 2 | 7 | 7 | 4 | 5 |
| Q2 2022 | 4 | 7 | 4 | 8 | -2 |
| Q3 2022 | 9 | 8 | 4 | 5 | -1 |
| Q4 2022 | 6 | 7 | 7 | 4 | 3 |
| Q1 2023 | 0 | 4 | 1 | 4 | 1 |
Hedge funds changes in Cyclacel Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 0 | 0 |
| Q4 2020 | 0 | 0 |
| Q1 2021 | 0 | 0 |
| Q2 2021 | 8,000 | 3,000 |
| Q3 2021 | 206,000 | 157,000 |
| Q4 2021 | 39,000 | 78,000 |
| Q1 2022 | 3,000 | 0 |
| Q2 2022 | 151,000 | 0 |
| Q3 2022 | 17,000 | 5,000 |
| Q4 2022 | 11,836 | 400 |
| Q1 2023 | 1,000 | 0 |